Remote working conditions for the design and testing of medical devices and combination products are here to stay. How can project leaders adapt to these new conditions while gathering input from their full teams, avoiding use errors and medication errors, and improving the patient experience? And with regulators not providing clear guidelines for decentralized testing,...
Larger Than Life Science is a free event series open to everyone interested in building a strong support network for biotech, life science, and healthcare innovators. Putting Your Best Foot Forward: Connecting with Pharma Partners and VCs Life science startups need strong partnerships to thrive. Making a meaningful connection to a pharma partner or key...
Acquiring the appropriate patient population and data for a clinical trial is no easy task, especially when that disease population is small or when data collection is complex. The recent expansion of virtual clinical trials landscape has created new recruiting opportunities; however, recruitment remains an ongoing challenge and a common reason for study failure. Moreover,...
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs,...
Induced pluripotent stem cells (iPSCs) hold great potential as therapies to repair damaged tissue or replace cell types missing due to genetic defects. However, even iPSCs derived from a patient can mutate in culture, causing immune rejection when they are re-transplanted. Being able to control immune rejection is key to using iPSCs as theraputics. The...
Artificial intelligence (AI) is rapidly reshaping the healthcare landscape, and redefining what is possible in life science. RESI AI is a partnering conference that connects the investors and strategic partners and matches them to companies developing and commercializing AI technology in drugs, devices, diagnostics, and digital health (the 4 Ds) to revolutionize healthcare. In addition to pitch sessions and one-on-one meetings hosted by our partnering platform,...
The aging boomer population contributed $8.3 trillion in economic activity to the 2018 US economy, and that number is projected to triple by 2050. The need for advancements in drugs, devices, diagnostics, and digital health for the treatment of age-related conditions is crucial. RESI Longevity is a new partnering conference focused on conditions related to...
We are excited to announce the fifth annual SoCal Genome Stability Symposium. The Symposium is coordinated in partnership by Scripps Research, City of Hope and the University of Southern California. The SoCal Genome Stability Symposium offers postdoctoral associates and graduate students the opportunity to present their current research and to connect with their peers from...
For 20 years, Bio-IT World has connected the people, ideas, and opportunities of the life science industry to accelerate R&D and drive the future of medicine. The 20th annual event will highlight how far we’ve come, celebrate new victories, and shed light on what’s next for biomedical research, drug discovery and development, and healthcare. Access...
Biocom California’s HR Conference for Life Science is dedicated to HR professionals working within the life science industry across the state of California. In 2021, this strategic-level conference will be delivered in a hybrid format. The statewide conference will take place over the span of three weeks, connecting the HR communities across California, and providing...
NOTE: 8:30-12:30 PST Drug interaction is an important consideration throughout drug development. Since each drug candidate has its unique drug interaction profile in the context of the intended indication, there are no universally accepted strategies for evaluating drug interaction potentials; however, but there are generally adopted drug interaction strategies and practices developed by the industry...
